Liu found that CCAT1 enhances CRC cell resistance to oxaliplatin by transcriptionally activating CCAT1 through B-MYB, increasing SOCS3 promoter methylation to recruit DNMT1, thereby inhibiting SOCS3 expression and enhancing CRC cell resistance to oxaliplatin (82). Here, SOCS3 is linked to colorectal carcinoma.